期刊文献+

P-gp、MRP、LRP、P53及c-erbB-2在非小细胞肺癌中的表达 被引量:6

Expression of P-glycoprotein,multidrug resistance associated protein,lung resistance-related protein,P53 and c-erbB-2 in non-small cell lung cancer
下载PDF
导出
摘要 目的:探讨P糖蛋白(P-gp)、多药耐药相关蛋白(MRP)、肺耐药蛋白(LRP)、P53蛋白及c-erbB-2蛋白在术前未经治疗的非小细胞肺癌(NSCLC)中的表达及相互间的关系。方法:采用免疫组化法检测78例NSCLC癌组织及15例癌旁肺组织(距癌灶5 cm)中P-gp、MRP、LRP、P53及c-erbB-2的蛋白表达情况。结果:免疫组化显示P-gp、MRP、LRP、P53及c-erbB-2在肺癌组织中的阳性表达率分别是65.4%(51/78)、39.7%(31/78)、56.4%(44/78)、53.8%(42/78)及43.6%(34/78),均显著高于癌旁肺组织中的表达水平(P<0.05);MRP和LRP蛋白表达在不同病理类型(腺癌、鳞癌及大细胞癌)之间比较均具有显著性差异(P分别为0.008和<0.001),LRP及P53蛋白表达在不同病理分化程度之间具有显著性差异(P分别为0.025和0.026);c-erbB-2表达与P-gp、MRP、LRP、P53均有相关性(Spearman相关系数分别为0.317、0.401、0.519和0.341,P值分别为0.005、<0.001、<0.001和0.002),P53与MRP之间(Spearman相关系数为=0.260,P=0.022)以及LRP与MRP之间(Spearman相关系数为0.371,P=0.001)有相关性。结论:P-gp、MRP、LRP、P53及c-erbB-2这些蛋白的表达在NSCLC的多药耐药形成及肿瘤的发生发展中可能具有一定的协同作用。 Objective:To investigate the expression of P-glycoprotein (P-gp), multidrug resistance-related protein (MRP), lung resistance-related protein (LRP), P53 and c-erbB-2 in untreated non-small cell lung cancer (NSCLC) and their relationship with each other. Methods: The expression of P-gp, MRP, LRP, P53 and c-erbB-2 was detected in the carcinoma tissues of 78 NSCLC patients and 15 adjacent normal lung tissues (5 cm apart from tumors) by means of immunohistochemistry. Results: The positive rates of P-gp, MRP, LRP, P53 and c-erbB-2 in tumor tissues were 65.4 %, 39.7 %, 56.4 %, 53.8 % and 43.6 %, respectively, all significantly higher than those in normal tissues(P〈0.05). There was also significant difference in MRP and LRP expression between different pathologic types of NSCLC(squamous cell carcinoma, adenocarcinoma, large cell carcinoma) (P= 0. 008 and G0. 001, respectively). Expression of LRP and P53 was also significantly different between different degrees of pathological differentiation (well, moderate, poor) (P=0. 025 and 0. 026, respectively). The expression of c-erbB-2 was correlated with those of P-gp, MRP, LRP and P53 (Spearman R=0. 317, 0. 401, 0. 519 and 0. 341, respectively;P=0. 005, G 0. 001, G0.001 and =0.002, respectively) ; the expression of P53 was correlated with that of MRP (Spearman R=0. 260,P= 0. 022) ; and the expression of LRP was correlated with that of MRP (Spearman R = 0. 371, P= 0. 001 ). Conelusion: Overexpression of P-gp, MRP, LRP, P53 and c-erbB-2 may play a cooperative role in the drug resistance and development of NSCLC.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2006年第5期474-478,共5页 Academic Journal of Second Military Medical University
基金 国家自然科学基金(30570836).~~
关键词 非小细胞肺癌 P糖蛋白 多药耐药相关蛋白 肺耐药蛋白 P53蛋白 C-ERBB-2蛋白 carcinoma,non-small-cell lung P-glycoprotein multidrug resistance-associated protein lung resistance-related protein P53 c-erbB-2
  • 相关文献

参考文献18

  • 1Lehnert M.Clinical multidrug resistance in cancer:a multifactor problem[J].Eur J Cancer,1996,32A:912-920.
  • 2Volm M,Koomagi R,Mattern J,et al.Protein expression profiles indicative for drug resistance of non-small cell lung cancer[J].Br J Cancer,2002,87:251-257.
  • 3Volm M,Mattern J,Efferth T,et al.Expression of several resistance mechanisms in untreated human kidney and lung carcinomas[J].Anticancer Res,1992,12:1063-1067.
  • 4彭忠民,罗静,王潍博,王晓航,陈景寒,兰守敏.耐药相关基因表达对Ⅲ期非小细胞肺癌新辅助化疗的临床预测价值探讨[J].癌症,2004,23(8):963-967. 被引量:7
  • 5Rybarova S,Hajdukova M,Hodorova I,et al.Expression of the multidrug resistance-associated protein 1 (MRP1) and the lung resistance-related protein (LRP) in human lung cancer[J].Neoplasma,2004,51:169-174.
  • 6Schneider J,Gonzalez-Roces S,Pollan M,et al.Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy[J].Breast Cancer Res,2001,3:183-191.
  • 7Thomas GA,Barrand MA,Stewart S,et al.Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumors and normal tissue as determined by in situ hybridisation[J].Eur J Cancer,1994,30A:1705-1709.
  • 8Soussi T,Legros Y,Lubin R,et al.Multifactorial analysis of p53 alteration in human cancer:a review[J].Int J Cancer,1994,57:1-9.
  • 9Seth P,Katayose D,Li Z,et al.A recombinant adenovirus expression wild type p53 induces apoptosis in drug-resistant human breast cancer cells:a gene therapy approach for durg-resistant cancers[J].Cancer Gene Ther,1997,4:383-390.
  • 10Chin KV,Ueda K,Pastan I,et al.Modulation of activity of the promoter of the human MDR1 gene by Ras and p53[J].Science,1992,255:459-462.

二级参考文献12

  • 1Volm M,Koomagi R,Mattern J,et al. Protein expression profiles indicative for drug resistance of non-small cell lung cancer [J]. Br J Cancer,2002,87(3):251- 257.
  • 2Yeh JJ,Hsu WH,Wang JJ,et al. Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with p-glycoprotein expression [J].Respiration,2003,70(1):32- 35.
  • 3Kawai H,Kiura K,Tabata M,et al. Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy [J]. Lung Cancer,2002,35(3):305- 314.
  • 4Rosell R,Gomez CJ,Camps C,et al. Preresectional chemotherapy in stage Ⅲ A non-small-cell lung cancer:a 7-year assessment of a randomized controlled trial [J]. Lung Cancer,1999,26(1):7- 14.
  • 5Izquierdo MA,van der Zee AG,Vermorken JB,et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma [J]. J Natl Cancer Inst, 1995,87(16):1230- 1237.
  • 6Jiao X,Krasna MJ. Clinical significance of micrometastasis in lung and esophageal cancer:a new paradigm in thoracic oncology [J]. Ann Thorac Surg. 2002,74(1):278- 284.
  • 7Elias AD,Skarin AT,Leong T,et al. Neoadjuvant therapy for surgically staged Ⅲ A N2 non-small cell lung cancer (NSCLC) [J]. Lung Cancer, 1997,17(1):147- 161.
  • 8Betticher DC,Hsu Schmitz SF,Totsch M,et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage Ⅲ A pN2 non-small-cell lung cancer: a multicenter phase Ⅱ trial [J]. J Clin Oncol,2003,21(9):1752- 1759.
  • 9Voltolini L,Luzzi L,Ghiribelli C,et al. Results of induction chemotherapy followed by surgical resection in patients with stage Ⅲ A (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy [J]. Eur J Cardiothorac Surg,2001,20(6):1106- 1112.
  • 10Trussardi A,Poitevin G,Gorisse MC,et al. Sequential overexpression of LRP and MRP but not P-gp 170 in VP16-selected A549 adenocarcinoma cells [J].Int J Oncol,1998,13(3):543- 548.

共引文献6

同被引文献84

引证文献6

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部